Phase 2, Multiple Ascending Dose Proof of Concept Study

NCT02710604 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Infectious Disease

Interventions

DRUG: CMX157
DRUG: TDF

Sponsor

ContraVir Pharmaceuticals, Inc.